Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ranibizumab biosimilar PF582
- Development stage
- Phase 2
- Lead developer
- Primrose Bio
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
PF582 is a biosimilar of ranibizumab, which is a monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A). By blocking VEGF-A, it prevents angiogenesis (the formation of new blood vessels), which is implicated in several retinal diseases. PF582 was developed as a biosimilar to Lucentis (ranibizumab) for the treatment of ophthalmologic conditions such as wet age-related macular degeneration, diabetic macular edema, and retinal edema. The drug demonstrated comparable safety and efficacy to Lucentis in phase 1/2 trials but its development has been discontinued[1][2][3][6].
- Other names
- ranibizumab biosimilarLucentis biosimilar
02
Targets
Beyond the preview
Go deeper on ranibizumab biosimilar PF582.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ranibizumab biosimilar PF582.